Palatin Technologies Reports the Commencement of P-II Trial Evaluating Bremelanotide to Treat Obesity
Shots:
- Palatin Technologies has reported the initiation of P-II trial evaluating bremelanotide to address obesity
- The randomized and double-blind P-II study is designed to assess the tolerability of bremelanotide (a melanocortin 4 receptor agonist) monotx. or in combination with tirzepatide (GLP-1/GIP) for treating patients (n=60) with obesity across the 5 US sites
- The primary endpoint of the study includes safety and increased effectiveness of bremelanotide co-administration with tirzepatide in obese patients. Topline results are anticipated in H2’24
Ref: Palatin Technologies | Image: Palatin Technologies
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
